VMET: Viamet Pharmaceuticals Holdings, LLC - Summary | Jitta

Viamet Pharmaceuticals Holdings, LLC

NASDAQ:VMET

Notice
Stock data is unavailable or the company’s delisted.
Price
n/a
Loss Chance
58.4%
0.33JITTA SCORE
n/a
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (40)
Recent Business Performance (45)
Financial Strength (0)
Return to Shareholders (10)
Competitive Advantage (0)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
0.33
n/a
3.05
186.26%
COMPANY DESCRIPTION
Viamet Pharmaceuticals Holdings, LLC, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antifungal agents based on its proprietary metalloenzyme medicinal chemistry platform. Its lead product candidate, VT-1161, is an oral agent that is in Phase IIa clinical trial development for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent in preclinical development for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for the treatment of invasive fungal infections. Viamet Pharmaceuticals Holdings, LLC is based in Durham, North Carolina.